HepQuant, a member of Fitzsimons Innovation Community, has received premarket approval from the U.S. Food and Drug Administration (FDA) for its SHUNT Liver Diagnostic Test, marking a significant regulatory milestone for the company’s liver disease diagnostic technology. The blood-based test measures liver function and helps clinicians identify certain patients with compensated cirrhosis who are unlikely…
GelSana Therapeutics, a member of Fitzsimons Innovation Community, has announced that two research collaborators, Babita Parajuli and Dr. Amy Wang, received the 2026 Robert B. Lindberg Basic Scientist Paper Award from the American Burn Association for research evaluating GelSana’s CleraFlex wound care technology. The award recognizes research demonstrating that CleraFlex significantly reduced bacterial burden and…
The Gates Institute at the University of Colorado Anschutz has received clearance from the U.S. Food and Drug Administration (FDA) to advance a novel CAR T-cell therapy into clinical testing for adults with relapsed or refractory acute myeloid leukemia. The milestone represents the first U.S. authorization for clinical testing of a CAR T-cell therapy targeting…
The Global Business Development division of the Colorado Office of Economic Development and International Trade (OEDIT) announced that 17 Colorado companies and eight researchers have been awarded Proof of Concept and Early-Stage Capital and Retention grants through OEDIT’s Advanced Industries Accelerator Program. Congratulations to the Fitzsimons Innovation Community Early-Stage Capital and Retention Grant Recipients: Onconaut…
Colorado BioScience Association (CBSA) announced the winners of its 22nd Annual Awards Celebration, recognizing the people and organizations advancing Colorado’s position as a leading hub for health innovation. The awards spotlight leaders whose work accelerates breakthrough discoveries and delivers impact for patients in Colorado and around the world. Dr. Katherine Goodman, Associate Professor at the…
Pharmaceutical Executive recently spoke with RheumaGen CEO Richard Freed about his career and the work the biotech is doing to find cures for autoimmune diseases.
Aurora City Council has approved a massive increase in allowable housing at Fitzsimons Innovation Community, a move intended to transform the bioscience campus into a full-fledged neighborhood. Fitzsimons CEO Kelly Brough called the change “an obligation” to honor the site’s history while shaping a future that attracts talent and builds community.
A change to the Fitzsimons Innovation Community’s master plan in Aurora will allow eight times more residential units to be built on the medical campus.The Aurora City Council on Monday approved an amendment to the general development plan that increases the Fitzsimons Innovation Community residential unit cap from 850 units to 7,266 new units. Changes…
A new approach for gene editing will get its shot in a common and chronic autoimmune disorder. Rheumatoid arthritis is an autoimmune disease that causes pain and swelling in the joints. It affects about one percent of the adult population. With its HLA gene editing approach, RheumaGen believes it can create a one-time cure for…
A startup is developing a new class of treatments for autoimmune diseases leveraging an approach to editing genes in the HLA family, which play a critical role in the immune system. RheumaGen, which spun out from the University of Colorado Anschutz Medical Campus, launched earlier this year with $15 million in Series A funding co-led…